What is Calcitonin Injection?
Calcitonin is a hormone that regulates calcium and phosphate tiers in the blood and helps to alter bone metabolism. Calcitonin injection is used as a therapy for osteoporosis, Paget's disorder of bone, hyperparathyroidism, or metastatic breast cancer. Calcitonin injections, additionally acknowledged as calcitriol or coscalcin injection is a medicine used for the therapy of osteoporosis and hyperparathyroidism. These medicines assist deal with prerequisites the place bones turn out to be greater fragile than common such as brittle bone disease. This remedy helps to decrease the breakdown of bone by way of stimulating new.
|Unit||Value (USD Million)|
|Key Companies Profiled||Asahi Kasei Pharma (Japan), Future Health Pharma (Switzerland), Novartis (Switzerland), Yingu (United Kingdom), DAPHAE (Switzerland), Qingdao Guoda (China), Shanghai No.1 Bio (China), Guilin Pharma (China), Hybio Pharmaceutical (China) (China), Chengdu List Pharma (China) and CSPC (China)|
The market study is broken down by Type (Elcatonin Injection and Salmon Calcitonin Injection) and major geographies with country level break-up.
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from Chinese will contribute to the maximum growth of Global Calcitonin Injection market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Asahi Kasei Pharma (Japan), Future Health Pharma (Switzerland), Novartis (Switzerland), Yingu (United Kingdom), DAPHAE (Switzerland), Qingdao Guoda (China), Shanghai No.1 Bio (China), Guilin Pharma (China), Hybio Pharmaceutical (China) (China), Chengdu List Pharma (China) and CSPC (China) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Calcitonin Injection market by Type, Application and Region.
On the basis of geography, the market of Calcitonin Injection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Calcitonin Injection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In 2021, Novartis AG (Sandoz) signed a settlement with Bio-Thera Solutions (China) to commercialize BAT1706 (proposed bevacizumab biosimilar through Bio-Thera Solutions) in the US, Europe, Canada, and different worldwide markets.
- Rising Geriatric Population
- Growing Prevalence of Osteoporosis
- Increasing Demand for Better Treatment Options
- Patent Expiry of Blockbuster Biologics and Research on New Indications
- Easy Availability of Other Medications for the First Line Treatment of Osteoporosis and Related Diseases
- Side Effects of Calcitonin Salmon
- Stringent Regulatory Norms
Key Target AudienceCalcitonin Injection Manufacturers, Calcitonin Injection Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Asahi Kasei Pharma (Japan), Future Health Pharma (Switzerland), Novartis (Switzerland), Yingu (United Kingdom), DAPHAE (Switzerland), Qingdao Guoda (China), Shanghai No.1 Bio (China), Guilin Pharma (China), Hybio Pharmaceutical (China) (China), Chengdu List Pharma (China) and CSPC (China) etc.
2. Can we have customized study for Calcitonin Injection Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Calcitonin Injection Market by 2027?
Analysts at AMA estimates Calcitonin Injection Market to reach USD Million by 2027.